請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26773
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡務亮(Wu-Liang Hwu),吳英璋(Yin-Chang Wu) | |
dc.contributor.author | Tsai-Tzu Lin | en |
dc.contributor.author | 林彩姿 | zh_TW |
dc.date.accessioned | 2021-06-08T07:24:58Z | - |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-17 | |
dc.identifier.citation | 一、中文部份
1. 戴正德、李明濱編著(2000)。醫學倫理導論。台北:教育部。 2. 李美雲、蕭正光、許淑蓮、張宏泰、徐南麗(2002)。乳癌患者不確定感及影響因素之探討。中華民國91年9月第1卷第3期。 3. 李明亮主編。Metabolic Disorders Taiwan Experience代謝性疾病-台灣經驗。2004。台北:行政院衛生署國民健康局。 4. 林怡君(1996)。疑陽性甲狀腺低能症患者母親之壓力源與調適行為。碩士論文。台北:國立台灣大學醫學院護理研究所。 5. 林毓婷(2005)。遺傳諮詢人員的介入對新生兒聽力篩檢陽性個案母親在知識、焦慮影響程度之探討。碩士論文。台北:國立台灣大學醫學院分子醫學研究所。 6. 羅鳳菊(2007)。先天性代謝異常疾病患童母親之親職壓力與生活品質之探討。碩士論文。台北:國立台灣大學醫學院分子醫學研究所。 7. 柯乃熒、蕭琪、許淑蓮(1997)。不確定感之概念分析。護理雜誌,44(1),92-97。 8. 許淑蓮、黃秀梨、林惠賢(1998)。急性心肌梗塞住院病人的不確定感與因應行為之探討。台灣醫學,2(5),498-508。 9. 胡淑貞、莊茹潔、王瑤華、黃怡瑾、林秀娟(2005)。遺傳諮詢提供者與利用者對現階段尚無治療之疾病遺傳檢測態度之差異。The Journal fo health Science。Vol 7, No. 3. pp.246-259。 10. 黃美智(2004)。透視新生兒篩檢.科學發展. pp.378. 11. 黃璉華(1997)。母血篩檢陽性非高齡孕婦與高齡孕婦焦慮程度之比較。行政院國家科學委員會專題研究計畫成果報告。台北:行政院衛生署。 12. 黃璉華(1998)。遺傳諮詢對減緩接受羊膜穿刺孕婦焦慮程度之成效。行政院國家科學委員會專題研究計畫成果報告。台北:行政院衛生署。 13. 黃璉華、戴玉慈(1998)。肌肉萎縮症患孩母親的心理社會衝擊。護理研究。6(2),pp.137-150。 14. 翁瑞亨、劉丹桂、黃璉華等合著(1999)。優生保健。台北:華杏出版股份有限公司。 15. 蔣思慧、蕭廣仁(2004)。國內新生兒先天代謝異常疾病篩檢項目增減可行性之探討。台北:行政院衛生署國民健康局. 16. 晉宏珍(2006)。海洋性貧血責任帶因者心理社會衝擊之研究。碩士論文。台北:國立台灣大學醫學院分子醫學研究所。 17. 許淑蓮(2001)。初患心肌梗塞病人不確定感與焦慮反應-因應行為效應之探討。護理研究,9(2),159-171。 18. 徐日慧茹、張至寧、蔡甫昌(2005)。基因檢測倫理。當代醫學。第32卷4期。pp.476-482。 19. 陳惠貞(2005)。情生命動-一位小腦萎縮症患者的生命歷程。碩士論文。南華大學。 20. 陳素珍(2005)。中部某醫院護理人員之遺傳學知識、態度與在職教育需求之探討。碩士論文。台北:國立台灣大學醫學院分子醫學研究所。 21. 陳彥元、蔡甫昌(2007)。臨床倫理諮詢。台灣醫學。中華民國96年11卷4期。Pp.431-437。 22. 蔡明儒(2005)。遺傳性神經退化性疾病之情緒研究-以脊髓小腦萎縮症及亨丁頓氏病為例。碩士論文。台北:國立陽明大學生命科學院遺傳研究所。 23. 沈淑滿(1995)。重型β型海洋性貧血患童父母親的壓力、因應方式與需求之探討。碩士論文。台北:國立台灣大學醫學院護理研究所。 24. 蔡甫昌(2000)。生命倫理四原則方法。醫學教育4(2),p12-26。 二、英文部分: 1. Baroni M. A., Anderson Y. E., Mischler, E. (1997). Cystic fibrosis newborn screening: impact of early screening results on parenting stress. Pediatric Nursing, 23(2), 143-51. 2. Bennett R.L., Hart K.A.,O’Rourke E., BArranger J.A., Johnson J., MacDermot K.D., Patores G.M., Steiner R.D., Thadhani R.,(2002). Fabry disease in genetic counseling practice: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling .Vol.11. No.2. pp.123-146. 3. Bernhardt B.A., Haunstetter C.M., Roter D., Geller G.,(2005). How do obstetric providers discuss referrals for prenatal genetic counseling? Journal of genetic coubseling.14 (2):109-117. 4. Bongiorno M.R., Pistone G., Aricò M., (2003). Fabry disease: enzyme replacement therapy. Journal of European Academy of Dermatology and Venereology. 17(6):676-670. 5. Branton M.H., Schiffmann R., Sabins S.G., Murray G., Quirk J.M., Altarescu G., Goldfarb L., et. al. (2002). Natural history of Fabry renal disease: influence of alpha-galactosidase an activity and genetic mutations on clinical course. Medicine. 81:122-38. 6. Brunger J. W., Muttay G.S., O’Riordan M., Matthews A.L., Smith R.J.H.,, Robin N. H.,(2000). Parental Attitudes toward Genetic Testing for Pediatric Deafness. The American Journal of Human Genetics. Volume 67, Issue 6, 1621-1625. 7. Burson C.M., Markey K.R., (2001).Genetic counseling issues in predictive genetic testing for familial adult-onset neurological diseases. Seminars in Pediatrics Neurology. 8(3); 177-186. 8. Burton S.K., Withrow K., Arnos K.S., Kalfoglou A.L., Pandya A.,(2006). A focus group study of consumer attitudes toward genetic testing and newborn screening for deafness. Genetics in Medicine. 8(12):779-83. 9. Ciske D.J., Haavisto A., Laxova A., Rock L.Z.M., Farrell P.M., (2001). Genetic Counseling and neonatal screening for cystic fibrosis: An assessment of the communication process. Pediatrics. Vol. 107. No.4. pp.669-705. 10. Clemens C.J., Davis S.A., Bailey A.R., (2000). The False-Positive in Universal Newborn Hearing Screening. Pediatrics.Vol.106. No.1. pp.1-5. 11. Clarke J.R., Iwanochko R.M., (2004). Enzyme replacement therapy of Fabry disease. Molecular Neurobiology. Vol. 32. pp. 43-50. 12. Clayton E.W., (1992). Issues in State Newborn Screening Programs. Pediatrics. Vol. 90 No.4. pp. 641-646. 13. Cox-Brinkman J., Vedder A., Hollak C., Richfield L., Mehta A., Orteu K., Wijburg F., Hammond P.,(2007).Three-dimensional face shape in Fabry disease. European Journal of Human Genetics. 15(5):535-542. 14. Crockett R., Wright A.J., Uus K., Bamford J., Marteau T.M., (2006).Maternal anxiety following newborn hearing screening: the moderating role of knowledge. Journal of Medical Screening.13:20-25. 15. Davis T. C., Humiston S. G., Arnold C.L., Bocchini J. A., et.al. (2000). Recommendations for Effective Newborn Screening Communication: Results of Focus Groups With Parents, Providers, and Experts. Pediatrics. Vol. 117 No. 5. pp. S326- 16. Davey A., French D., Dawkins H., A’Leary P., (2005). New mothers’ awareness of newborn screening, and their attitudes to the retention and use of screening samples for research purposes. Genomics, Society and Policy. Vol.1. No.3. pp.44-51. 17. Decruyenaere M., Evers-Kiebooms G., Boogaerts A., Demyttenaere K., Dom R., Fryns J.P., Predictive testing for huntingtons disease relationship withpareners after testing. Clinical Genetics. 65(1):24-31. 18. Deegan P.B., Baehner A.F., Konero M-A B., Hughes D.A., et. al. (2006). Natural history of Fabry disease in females in the Fabry Outcome Survey. Journal of Medical Genetics. 43:347-352. 19. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., et. al. (2001).A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. American Journal of Human Genetics. 68(3):711-22. 20. Gurian E.A., Kinnamon D.D., Henry J.J., Waisbren S.E., (2006).Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics.117(6):1915-21. 21. Eto Y., Ohashi T., Utsunomiya Y., Fujiwara M., et. al. (2005).Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. Journal of Inheriented Metabolic disease. 28(4):575-83. 22. Fuller M., Lovejoy M., Brooks D.A., Harkin M.L., Hopwood J.J., Meikle P.J., (2004). Immunoquatification of a-galactosidase: Evaluation for the diagnosis of Fabry disease. Clinical Chemistry, 50. No.11. pp.1979-1985. 23. Fyrö K, Bodegård G., (1987). Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism. Acta Paediatrica Scandinavica. 76(1):107-114. 24. Geller G., Tambor E.S., Bernhardt B.A., Fraser G., Wissow L.S.,(2005).Informed consent for enrolling minors in genetic susceptibility research: a qualitative study of at-risk children's and parents' views about children's role in decision-making. Journal of Adolescence Health. 32(4):260-271. 25. Hall S., Bobrow M., Marteau T.M.,(2000).Psychological consequences for parents of false negative results on prenatal screening for Down's syndrome: retrospective interview study. British Medical Journal. 320:407-412. 26. Hamann H.A., Croyle R.T., Venne V.L., Baty B.J., Smith K.R., Botkin J.R.,(2000). Attitudes toward the genetic testing of children among adults in Utah-based kindred tested for a BRCA1 mutation. American Journal of Medical Genetics.92(1):25-32. 28. Hoffmann B., Lovenzo G., Mohtu A., Beck M., et. al. (2005). Effects of enzyme replacement therapy on pain and disease: data from Fabry Outcome Survey. Journal of Medical Genetics. 42:247-252. 29. Hughes C., Gomez-Caminero A., Benkendorf J., Kerner J., Isaacs C., Barter J., Lerman C.,(1997). Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Education Counseling. 32:51-62. 30. Kemper A.R., Hwu W.L., Puryear M.L., Kishnani P.S., (2007); 92(1):25-32. 31. . Newborn Screening for Pompe Disease: Synthesis of the Evidence and Development of Screening Recommendations. Pediatrics. Vol.120. No.5. pp.1327-1334. 32. Kinney A.Y., Croyle R.T., Dudley W.N., Bailey C.A., Pelias M.K., Neuhauseen S.L.,(2001). Knowledge, attitudes, and interest in Breast-Ovarian cancer gene testing: a survey of large African-American kindred with a BRCA1 mutation. Preventive. Medicine. 33, pp. 543-551. 33. Kotanko P., Kramar R., Devrnja D., et.al. (2004). Results of Nationwide screening for Anderson-Fabry disease among dialysis patients. Journal of American Society Nephrology. 15:1323-1329. 34. Kreuz F.R., (1996). Attitudes of German persons at risk for Huntington's disease toward predictive and prenatal testing.. Genetic Counseling. 7(4):303-311. 35. Mastromauro C., Myers R.H., Berkman B., (1987). Attitudes toward Genetics. 26(2):271-282. 36. Markel D.S., Young A.B., Penney J.B.,(1987).At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. American Journal of Medical Genetics.26 (2):295-305. 37. Welkenhuysen M., Evers-Kiebooms G., Van den Berghe H.,Attitudes towardpredictive testing for Alzheimer's disease in a student population. Psychiatrics Genetics.7 (3):121-6. 38. Mérelle M.E., Huisman J., Alderden-van der Vecht A., Taat F., Bezeme r D.,Griffioen R.W., Brinkhorst G., Dankert-Roelse J. E.,(2003). Early Versus Late Diagnosis: Psychological Impact on Parents of Children with Cystic Fibrosis.Pediatrics. 111(2):346-350. 39. Masson C., Cesse I., Simon V., Insalaco P., AMdran M.,(2004). Fabry disease: a review. Joint Bone Spine. 71:381-383. 40. Parsons E. P., Clarke A.J., Hood K., Lycett E., Bradley D.M., (2002). Newbornscreening for Duchenne muscular dystrophy: a psychosocial study. ArchivesDiseases in Childhood: Fetal and neonatal edition. Mar; 86(2):F91-95. 41. Pastores GM, Thadhani R. (2002). Advances in the management ofAnderson-Fabry disease: enzyme replacement therapy. Expert of OpinionBiological Therapy. 2 (3):325-33. 42. Quinlivan J.A., Suriadi C., (2006).Attitudes of New Mothers towards Genetics andNewborn Screening.http://www.redorbit.com/news/display/?id=546820. 43. Richards F., (2004). Couples' experiences of predictive testing and living with therisk or reality of Huntington disease: a qualitative study. American Journal ofMedical Genetics.126A (2):170-82. 44. Rosen A., Wallenstein S., McGovern M. M., (2002).Attitudes of pediatric residentstoward ethical issues associated with genetic testing in children. Pediatrics. Vol.110. No. 2. pp. 360-363. 45. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H.,Ponzone A., Desnick R.L., (2006). High incidence of later-onset Fabry diseaserevealed by newborn screening. The American journal of Human Genetics. Vol.79.pp.31-40. 46. Richards F., William K., (2004). Impact on couple relationships of predicativetesting for Huntington disease: a longitudinal study. American Journal of MedicalGenetics. 126A (2); 162-169. 47. Tan E.K., Lee J., Hunter C., Shinawi L., Fook-Chong S., Jankovic J., (2007).Comparing knowledge and attitudes towards genetic testing in Parkinson's diseasein an American and Asian population. Journal of the Neurological Sciences.252(2):113-120. 48. Tluczek A, Mischler EH, Farrell PM, Fost N, Peterson NM, Carey P, Bruns WT,McCarthy C.(1992). Parents' knowledge of neonatal screening and response tofalse-positive cystic fibrosis testing. Journal of Development BehaviorPediatrics.13 (3):181-186. 49. Vohr B.R., Krauzyk J.J., Tucker R., Johnson M. J.Topol D., Ahlgren M., (2008).Results of newborn screening for hearing loss: effects on the family in the first twoyears of life. Archives of Pediatrics Adolescent Mediceine. Vol. 162. No.3.pp.203-211. 50. Vohr B.R., Letourneau K.S., McDermott C., (2001). Maternal worry aboutneonatal hearing screening. Journal of Perinatology. 21(1):15-20. 51. Wraith J., Tylki-Szymanska A., Lien Y., Tsimaratos M., Vellodi A., Germain D.,(2008). Safety and Efficacy of Enzyme Replacement Therapy with AgalsidaseBeta: An International, Open-label Study in Pediatric Patients with Fabry Disease.The Journal of Pediatrics, Vol.152 (4):563-70. 52. Waisbren S., Gurian E., (2006).Newborn Screening Can Cause UnnecessaryParental Stress. www.health.com. 53. Parental attitudes toward newborn screening: a review of literature. The Americancollege of medical Genetics. 2006. Annual clinical genetics Meeting. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26773 | - |
dc.description.abstract | 研究背景:串聯質譜儀篩檢技術迅速發展,使得許多代謝性疾病在新生兒篩檢被偵測出來。法布瑞氏症新生兒篩檢先導計畫目前已經開始進行,法布瑞氏症是晚發性疾病,其篩檢方法和現有之篩檢項目有比較大的不同。研究目的:本研究想探討父母對布瑞氏症的了解情形,從中了解父母接受預測性檢測的意願、以及新生兒篩檢結果可能帶給對父母產生的心理影響,未來在新生兒篩檢前提供適當的遺傳諮詢以及訊息。研究方法:研究對象來源主要來自新生兒篩檢室提供的名單和基因醫學部門診病人,符合研究調查之條件進行自填式問卷、郵寄問卷或採取電話訪談方式進行資料收集,收案人數共有76 份。研究對象分為接受新生兒法布瑞氏症篩檢需複檢之父母親為本研究之實驗組,蠶豆症需複檢之父母親為對照組。
研究結果:父母接到電話通知小孩新生兒篩檢需要複檢時,大多感受到中等或很大的壓力,情緒反應大多呈現震驚和焦慮。實驗組接受法布瑞氏症遺傳諮詢有76%,接受遺傳諮詢對法布瑞氏症的了解顯著高於未接受遺傳諮詢的受試者。實驗組對法布瑞氏症的了解顯著高於對照組。兩組新生兒晚發性預測性檢測的認知程度則無統計上差異。如果疾病可經治療或預防會有更好的預後,實驗組有88%同意接受讓小孩接受預測性檢測;對照組則有85%同意。如果預測性檢測準確度只有50%,57%實驗組同意接受;對照組有78%願意接受。實驗組有76%願意考慮讓小孩接受糖尿病、高血壓等多因子的疾病檢測; 對照組則有63%願意接受。對於不可治療的晚發性亨丁頓氏症舞蹈症,61%實驗組會接受預測性檢測;56%對照組也願意接受檢測。結論:研究對象在得知新生兒需要進行法布瑞氏症複檢時比需要蠶豆症複檢在情緒上產生較高的震驚和焦慮,並感受到較大的壓力。實驗組對法布瑞氏症的了解則高於對照組。接受過遺傳諮詢對法布瑞氏症的了解高於未接受遺傳諮詢的受試者。可見遺傳諮詢的重要性,可以協助父母親對新生兒篩檢的了解。在未來的諮詢發展遺傳諮詢的需求和法布瑞氏症知識的宣導是不可輕忽的。 | zh_TW |
dc.description.abstract | Background: The development of Tandem Mass Spectrometry has just increased dramatically the number of diseases that can detected by newborn screening, but now new tests including Fabry disease are starting. Fabry disease is different from other diseases targeted by newborn screening that it is a late-onset disease. Therefore, it would be important to know the attitudes of the parents toward Fabry disease. Purposes: In this study we want to assess parents’ knowledge about Fabry screening, and their reaction to a positive screening result. Methods: A questionnaire would be filling in through mail-in survey, face to face interview, or by telephone. Each participant took 20 minutes to fill out the questionnaire completely. Questions included demographic variables, psychological consequences, knowledge of Fabry disease and late-onset predictive, and attitude towards predictive testing. Two groups’ subjects were recruited. The experiment group was the parents whose children received Fabry disease newborn screening; the control group was the parents whose children received G6PD newborn screening. A total of 76 subjects were enrolled in this study. Results: 76 questionnaires were analyzed by SPSS 12.0. Most of parents felt moderated or severe pressure when the hospital informed them to repeat the newborn screening test because the false- positive result. Parents often appeared shock and anxiety in both participant groups. 76% of parents in the experiment group had received genetic counseling. The knowledge about Fabry disease was better in the experiment group than in the control group. 88% of parents in the experiment group agreed to do the predictive test for their children if the disease has good prognosis after treatment, while 85% in the control group agreed. 57% of parents in the experiment group agreed to do the predictive testing even the detection rate was 50%, while 78% in the control group agreed. 76% in the experiment group agreed to do the genetic testing for multiple factorial diseases, while 63% in the control group agreed. 61% in the experiment group agreed to do the predictive test for untreatable disease such as Huntington disease, while 56% in the control group agreed. Conclusions: There’s a significant difference between the two groups in the knowledge of Fabry disease. Among the emotional responses, shock and anxiety were higher upon a positive screening result for Fabry disease and the Fabry disease of pressure was also high. It appeared that genetic counseling was important for the parents to understand newborn screening. Subjects who had received counseling had better knowledge in the Fabry disease than subjects who didn’t receive counseling. The needs for counseling and knowledge about Fabry disease should not be neglected in the development of the screening program.
Keywords: Fabry disease, False-positive, late-onset disease, Predictive test. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:24:58Z (GMT). No. of bitstreams: 1 ntu-97-P95448007-1.pdf: 724848 bytes, checksum: 7cafe3e11e8361d79ba7131656f43a9c (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 致謝 ………………………………………………………………………………..4
中文摘要 …………………………………………………………………………..5 英文摘要 …………………………………………………………………………..6 第一章 緒論 ………………………………………………………………………8 第一節 研究背景和動機 ……………………………………………………8 第二章 文獻探討 ………………………………………………………………..10 第一節 新生兒篩檢 ………………………………………………………..10 第二節 法布瑞氏症 ………………………………………………………..15 第三節 民眾對預測性檢測態度及檢測過程中的心理反應 ……………..20 第四節 名詞界定……………………………………………………………23 第三章 研究架構和研究假設 …………………………………………………..24 第一節 研究目的 …………………………………………………………..24 第二節 研究架構 …………………………………………………………..25 第三節 研究假設……………………………………………………………26 第四章 研究方法 ………………………………………………………………..27 第一節 研究對象 …………………………………………………………..27 第二節 研究工具 …………………………………………………………..28 第三節 研究倫理 …………………………………………………………..31 第四節 研究收案期間 ……………………………………………………..31 第五節 資料分析 ….. ……………………………………………………...32 第五章 研究結果 ….……………………………………………………….…..33 第一節 基本屬性之描述 …………………………………………………..33 第二節 新生兒篩檢結果之情緒反應及感受到的壓力分析 ……………..38 第三節 法布瑞氏症的了解之分析 ………………………………………..50 第四節 新生兒篩檢預測性檢測認知與行為之分析 ……………………..55 第六章 討論 ……………………………………………………………………..60 第一節 基本屬性探討 ……………………………………………………..60 第二節 新生兒篩檢結果的情緒反應探討 ..…………………………… ...61 第三節 新生兒篩檢需要複檢感受到的壓力探討 .……………………….63 第四節 法布瑞氏症的了解之探討 ………………………………………..65 第五節 遺傳諮詢與法布瑞氏症、新生兒篩檢預測性檢測的認知影響 ..67 第七章 建議…….……………………………………………………………….. 68 第八章 研究限制 ……….……………………………………………………….69 附件一 ……………………………………………………………………………70 附件二 ……………………………………………………………………………71 附件三 ……………………………………………………………………………72 參考文獻 ………………………………………………………………………80 | |
dc.language.iso | zh-TW | |
dc.title | 家長對晚發性疾病新生兒篩檢之態度探討-以法布瑞氏症為例 | zh_TW |
dc.title | Parents' attitude toward screening for late-onset diseases-A study of Fabry disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李銘仁 | |
dc.subject.keyword | 法布瑞氏症,疑陽性,晚發性疾病,預測性檢測, | zh_TW |
dc.subject.keyword | Fabry disease,false-positive,late-onset disease,predictive test, | en |
dc.relation.page | 88 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 707.86 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。